Health Economics›Esophageal adenocarcinoma›Metastatic or locally advanced disease first-line

Metastatic or locally advanced disease first-line

Esophageal adenocarcinoma · 16 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 11 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Capecitabine and Cisplatin (CX) and Cetuximab Variant #01	—	R 56 329	21d	4.4 mo	—	3	R 95 759 PFS proxy	1
Erlotinib monotherapy Variant #01	—	R 13 907	28d	~9.7 mo	~8.8 mo	~2	~R 27 814 PFS proxy · indirect	30
FLOT Variant #02	—	R 5 524	14d	—	~50.0 mo	~6	~R 21 885 PFS proxy · indirect	2
mFOLFOX6 and Nivolumab Variant #01 Partial	—	R 3 180	14d	7.7 mo	14.4 mo	2	R 6 359 PFS proxy	2
CAPIRI Variant #05	—	R 2 849	21d	~5.9 mo	~16.8 mo	~9	~R 25 642 PFS proxy · indirect	2
Irinotecan monotherapy Variant #01	—	R 2 716	42d	~2.3 mo	~8.5 mo	~11	~R 29 874 PFS proxy · indirect	16
ECX Variant #01	—	R 2 632	21d	4.2 mo	—	3	R 7 896 PFS proxy	1
CapeOx Variant #01	—	R 2 620	21d	~6.7 mo	~12.2 mo	~6	~R 15 719 PFS proxy · indirect	20
CapeOx and Nivolumab Variant #01 Partial	—	R 2 620	21d	7.7 mo	14.4 mo	2	R 5 240 PFS proxy	2
mFOLFOX6 Variant #02	—	R 2 617	14d	—	11.6 mo	2	R 5 233 PFS proxy	—
FOLFIRI Variant #05	—	R 2 314	14d	~8.2 mo	~16.1 mo	~5	~R 11 572 PFS proxy · indirect	22
FOLFOX6 Variant #01	—	R 2 212	14d	~6.7 mo	—	~2	~R 4 424 PFS proxy · indirect	—
mFOLFOX6 (L-Leucovorin) Variant #01 Partial	—	R 2 054	14d	—	11.8 mo	12	R 24 643 PFS proxy	—
Irinotecan and Mitomycin Variant #01	—	R 2 040	28d	—	—	~7	~R 14 280 indirect	—
Capecitabine and Cisplatin (CX) Variant #01	—	R 1 480	21d	5.6 mo	—	2	R 2 960 PFS proxy	1
Cisplatin and Fluorouracil (CF) Variant #01	—	R 1 235	28d	—	8.6 mo	3	R 3 706 PFS proxy	1

16 of 16 regimens shown